In Vitro Antimicrobial Assessments 2011-2018

The In Vitro Antimicrobial Assessments 2011-2018 Master Indefinite Delivery/Indefinite Quantity (IDIQ) contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to support advanced scientific research in antimicrobial and antiviral assessment. The contract's primary objective was to develop and provide in vitro assays that advance the understanding and development of therapeutics for infectious diseases. By creating this multi-award contract vehicle, NIAID sought to promote cross-disciplinary collaboration, efficiently utilize research resources, and maintain flexibility in responding to evolving research priorities.

The task orders under this IDIQ consistently focused on in vitro assessments of antimicrobial and antiviral activity, with contract values ranging from $25,000 to over $1 million. Prime contractors frequently included academic research institutions such as the University of Alabama at Birmingham, Utah State University, University of Texas Health Science Center at San Antonio, Georgetown University, and Southern Research Institute. Task orders typically had performance periods between six months and one year, with firm fixed-price pricing structures. No set-aside designations were used across the vehicle's task orders. The work was predominantly performed at university research facilities located in states like Texas, Alabama, Utah, and Colorado, supporting NIAID's mission of developing medical countermeasures against viral, bacterial, and fungal pathogens through specialized laboratory testing and research services.